Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer

Autor: Eva‐Maria Birkman, Adam Elzagheid, Terhi Jokilehto, Tuulia Avoranta, Eija Korkeila, Jarmo Kulmala, Kari Syrjänen, Jukka Westermarck, Jari Sundström

Publikováno v: Cancer Medicine, Vol 7, Iss 3, Pp 698-706 (2018)

Abstract Preoperative (chemo)radiotherapy, (C)RT, is an essential part of the treatment of rectal cancer patients, but tumor response to this therapy among patients is variable. Thus far, there are no clinical biomarkers that could be used to predict

Externí odkaz: https://doaj.org/article/35cd0077427f43e2ae803cbb310456a8

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Autor: Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard Epstein, Paul Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall Tebbutt, Gerald Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp-Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean-Luc Van Laethem, Stéphanie Laurent, Neesha Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke Parner, Tapio Salminen, Leena-Maija Soveri, Eija Korkeila, Pia Osterlund, Julien Taieb, David Tougeron, Pascal Artru, François Xavier Caroli-Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus-Alexander Wörns, Holger Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balazs Juhasz, László Landherr, Tamas Pinter, György Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek Power, Luca Gianni, Salvatore Siena, Michele Milella, Alfredo Falcone, Rossana Berardi, Cinzia Bagalà, Francesco Di Costanzo, Fausto Roila, Andrea Ardizzoni, Evaristo Maiello, Silvia Fanello, Johanna Wilmink, Jan Willem de Groot, Geert Creemers, Eduardo Barroso, Tânia Rodrigues, Cristina Sarmento, Cheng Ean Chee, David Tai, Teresa Macarulla Mercade, Manuel Hidalgo Medina, Alfredo Carrato Mena, Joan Maurel Santasusana, Maria Jose Flor Oncala, Carlos Gomez Martin, Rafael Lopez, Andres Muñoz, Ruth Vera Garcia, Inmaculada Ales, Berta Laquente Sáez, Fernando Rivera, Javier Sastre, Cheng-Chung Wu, Yu-Wen Tien, De-Chuan Chan, Tsann-Long Hwang, Jeffry Evans, Jonathan Wadsley, Pippa Corrie, Andrew Biankin, Andrew Ko, Dana Cardin, Elena Chiorean, Johanna Bendell, Anne Noonan, Hedy Kindler, Nishan Fernando, Muhammad Beg, Thomas George, Marcus Noel, Noelle LoConte, Francis Arena, James Posey, Rajat Malhotra, Charles Lopez, Davendra Sohal, Robert McWilliams, Warren Brenner, Mark Womack, Rahul Seth, Renuka lyer, Nathan Bahary, Robert Marsh, Robert Ramirez, Cynthia Chua, James Reeves, Gulam Manji, Anthony El-Khoueiry, Robert Weaver, Vaibhav Sahai, Wells Messersmith, Robert Dreicer, Ahmed Zakari, Andrea Bullock, Benjamin Musher, Mitesh Borad, Edward Kim, David Bajor, Tim Huyck, Hassan Hatoum, Henry Xiong, Boris Pasche, Jill Lacy, Olugbenga Olowokure, Allen Cohn, Donald Richards, Robert Martin, Andrew Paulson, Paul Fanta, Smitha Krishnamurthi, Paul Oberstein, Jyotsna Fuloria

Publikováno v: Scientia

PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METHODS We assi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::192d001f322850ad486a84bac981c740
https://lirias.kuleuven.be/handle/20.500.12942/715374

Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy:a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial)

Autor: Veera V. Salminen, Eila Lantto, Tuija Poussa, Raija Kallio, Maija Lavonius, Raija Ristamäki, Markus J. Mäkinen, Eija Pääkkö, Jari Sundström, Eetu Heervä, Sirpa Leppä, Johanna Mattson, Ari Ristimäki, P.J. Osterlund, Arno Nordin, Eija Sutinen, Eija Korkeila, T. Salminen, Kaisa Lehtomäki, Aki Uutela, P. Ryymin, Irina Rinta-Kiikka, Riikka Huuhtanen, Ali Ovissi, Olli Carpén, Marjut Timonen, Jani Saunavaara, Nina Lundbom, Heikki Mäkisalo, A.I. Hakkarainen, P. Halonen, Eveliina Lammentausta, Annika Ålgars, Helena Isoniemi, Johanna Virtanen, L. M. Soveri, R. Blanco Sequeiros, Nieminen Lasse, Niina Paunu, Heidi Penttinen, E. Liukkonen, Petri Bono, Siru Mäkelä, Martine Vornanen, Emerik Osterlund, Juhani Kosunen

Publikováno v: ESMO Open

Background Colorectal cancer liver metastases respond to chemotherapy and targeted agents not only by shrinking, but also by morphologic and metabolic changes. The aim of this study was to evaluate the value of advanced magnetic resonance imaging (MR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f9ddcc105fe6b21373dbe71abb69349
http://urn.fi/urn:nbn:fi-fe2022030221470

EGFR gene copy number decreases during anti-EGFR antibody therapy in colorectal cancer

Autor: Eva-Maria Birkman, Jari Sundström, Olli Carpén, Laura Lahtinen, Teijo Kuopio, Annika Ålgars, Eija Korkeila, Raija Ristamäki, Minnamaija Lintunen, Tuulia Avoranta

Publikováno v: Human Pathology. 82:163-171

Epidermal growth factor receptor (EGFR) gene copy number (GCN) increase is associated with a favorable anti-EGFR antibody treatment response in RAS wild-type metastatic colorectal cancer. However, there are limited and comparative data regarding the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d1bbf1986d13fa4517dd3ef192bba1c
https://doi.org/10.1016/j.humpath.2018.07.028

CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal Carcinoma

Autor: Khadija Slik, Samu Kurki, Riku Turkki, Teijo Pellinen, Olli Carpén, Jari Sundström, Eija Korkeila

Publikováno v: The American journal of surgical pathology. 43(11)

Current risk factors in stage II colorectal carcinoma are insufficient to guide treatment decisions. Loss of CDX2 has been shown to associate with poor clinical outcome and predict benefit for adjuvant chemotherapy in stage II and III colorectal carc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d81e55110f3b6c9dd44e5aaeabcf9a6
https://pubmed.ncbi.nlm.nih.gov/31490234